Cook GJ - Search Results

1

Discovery of pre-therapy 2-deoxy-2-¹⁸F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients.

Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, Scarsbrook A, McDermott G, Cook GJ, Landau D, Chua S, O'Connor R, Dickson J, Power DA, Barwick TD, Rockall A, Aboagye EO. Arshad MA, et al. Among authors: cook gj. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):455-466. doi: 10.1007/s00259-018-4139-4. Epub 2018 Sep 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30173391 Free PMC article.

2

Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

Cook GJ, Fogelman I, Maisey MN. Cook GJ, et al. Semin Nucl Med. 1996 Oct;26(4):308-14. doi: 10.1016/s0001-2998(96)80006-7. Semin Nucl Med. 1996. PMID: 8916319 Review.

3

Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine.

Cook GJ, Maisey MN, Fogelman I. Cook GJ, et al. Eur J Nucl Med. 1999 Oct;26(10):1363-78. doi: 10.1007/s002590050597. Eur J Nucl Med. 1999. PMID: 10541839 Review.

4

Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions.

Cook GJ, Lodge MA, Marsden PK, Dynes A, Fogelman I. Cook GJ, et al. Eur J Nucl Med. 1999 Nov;26(11):1424-9. doi: 10.1007/s002590050474. Eur J Nucl Med. 1999. PMID: 10552083

5

The role of positron emission tomography in skeletal disease.

Cook GJ, Fogelman I. Cook GJ, et al. Semin Nucl Med. 2001 Jan;31(1):50-61. doi: 10.1053/snuc.2001.18746. Semin Nucl Med. 2001. PMID: 11200205 Review.

6

Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography.

Cook GJ, Fogelman I. Cook GJ, et al. Q J Nucl Med. 2001 Mar;45(1):47-52. Q J Nucl Med. 2001. PMID: 11456375 Review.

7

Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.

Cook GJ, Wegner EA, Fogelman I. Cook GJ, et al. Semin Nucl Med. 2004 Apr;34(2):122-33. doi: 10.1053/j.semnuclmed.2003.12.003. Semin Nucl Med. 2004. PMID: 15031812 Review.

8

Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma.

Lee YK, Cook G, Flower MA, Rowbottom C, Shahidi M, Sharma B, Webb S. Lee YK, et al. Radiother Oncol. 2004 Dec;73(3):277-83. doi: 10.1016/j.radonc.2004.07.029. Radiother Oncol. 2004. PMID: 15588871 Clinical Trial.

9

Positron emission tomography and bone metastases.

Fogelman I, Cook G, Israel O, Van der Wall H. Fogelman I, et al. Semin Nucl Med. 2005 Apr;35(2):135-42. doi: 10.1053/j.semnuclmed.2004.11.005. Semin Nucl Med. 2005. PMID: 15765376 Review.

10

Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer.

Lavrenkov K, Partridge M, Cook G, Brada M. Lavrenkov K, et al. Radiother Oncol. 2005 Oct;77(1):1-4. doi: 10.1016/j.radonc.2005.09.016. Epub 2005 Oct 12. Radiother Oncol. 2005. PMID: 16225943 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

266 results

Search Page

Filters